International R&D Conference 2012
Video of the 3rd Research and Development Press Conference
Value through Innovation16 January 2013
Living. Breathing. Advancing. - Insights into the (respiratory) pipeline of Boehringer Ingelheim
At the 3rd international Research & Development press conference, insights into the company’s
R&D strategy, the product portfolio and the development-pipeline of the company were provided.
R&D Day 2012 at the largest of Boehringer Ingelheim’s R&D sites: Biberach, Germany
Details of the pipeline in Respiratory in the areas of Chronic Obstructive Pulmonary Disease (COPD), Asthma, Idiopathic Pulmonary Fibrosis (IPF) and Lung Cancer (NSCLC) were shared. Seven speakers including an external expert also showcased the broad range of respiratory indications that Boehringer Ingelheim may have new treatment options for in the foreseeable future.
Presentations
- Prof. Andreas Barner: Welcome and introduction to R&D at Boehringer Ingelheim (PDF, 1.5 MB)
- Prof. Wolfgang Rettig: Meeting the challenges of research – today (PDF, 1.6 MB)
- Prof. Klaus Dugi: Walking the extra mile – clinical research at Boehringer Ingelheim (PDF, 2.3 MB)
- Prof. Florian Gantner: Research & development in practice: COPD (PDF, 1 MB)
- Dr.Dr. Bernd Disse: An exclusive look at asthma (PDF, 1.4 MB)
- Prof. Luca Richeldi: Research & development in practice: IPF (PDF, 1.8 MB)
- Dr. Mehdi Shahidi: Research & development in practice: lung cancer (PDF, 923 KB)
-
R&D Conference 2012
Welcome to Boehringer Ingelheim`s Research and Development Day 2012 at Biberach/ Riss, Germany.
Boehringer Ingelheim to explore new avenues for patients with COPD, asthma, idiopathic pulmonary fibrosis, lung cancer and other respiratory diseases
Prof Andreas Barner, Chairman of the Board of Managing Directors at Boehringer Ingelheim, and scientist within Boehringer Ingelheim's own R&D division in Biberach, Germany revealed details of the company’s extensive overall pipeline.
Prof Andreas Barner highlighted the company's commitment to innovative research and development programmes despite additional complexity, increased cost, and regulatory or market access hurdles.
"In the past decade Boehringer Ingelheim has conducted 1,348 studies in 111 countries across all our therapeutic areas within our own global Research and Development organisation with 7,000 colleagues in R&D and Medicine." said Prof Andreas Barner.
Challenging times lie ahead in the development of breakthrough innovations for clinical and medical research.
'Walking an extra mile' at Boehringer Ingelheim with regard to many aspects of clinical trials.
